UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): July 30, 2012
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Michigan |
|
000-22025 |
|
94-3096597 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
24 Frank Lloyd Wright Drive, P.O. Box |
|
|
|
48106 |
(Address of principal executive offices) |
|
|
|
(Zip Code) |
Registrants telephone number, including area code: (734) 418-4400
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On July 30, 2012, Aastrom Biosciences, Inc. (the Company) issued a press release announcing the results of its previously announced offer to exchange (the Exchange Offer) any warrant to purchase shares of common stock, no par value per share, of the Company issued in connection with the Companys December 2010 public offering, that was tendered and accepted, for shares of the Companys common stock. Such Exchange Offer was made upon the terms and subject to the conditions set forth in the Companys offer to exchange, dated June 28, 2012, and in the related Exchange Offer materials filed as exhibits to the Tender Offer Statement on Schedule TO originally filed with the Securities and Exchange Commission on June 28, 2012, as amended. The Exchange Offer expired at 5:00 p.m., Eastern Standard Time, on Friday, July 27, 2012.
The press release is attached hereto as Exhibit 99.1 hereto and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
|
Description |
99.1 |
|
Press Release, dated July 30, 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Aastrom Biosciences, Inc. | |
|
| |
Date: July 30, 2012 |
By: |
/s/ Tim M. Mayleben |
|
|
|
|
|
Name: Tim M. Mayleben |
|
|
Title: Chief Executive Officer and President |
Exhibit 99.1
Aastrom Biosciences | |
Dominos Farms, Lobby K | |
24 Frank Lloyd Wright Drive | |
Ann Arbor, MI 48105 | |
T 734 4184400 F 734 6650485 | |
www.aastrom.com |
Aastrom Announces Results of Common Stock Exchange for December 2010 Warrants
ANN ARBOR, Mich., [July 30, 2012] Aastrom Biosciences, Inc. (Nasdaq: ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announced today that it has completed the previously announced exchange of its outstanding December 2010 warrants for common stock. As of July 27, 2012, when the companys offer to exchange these warrants for common stock expired, 9,691,900 warrants had been exchanged for 4,845,949 shares of common stock. This total includes warrants that were part of a private exchange on June 27, 2012. There now remain 308,100 December 2010 warrants outstanding with an exercise price of $3.22 and an expiration date of December 15, 2015.
We are extremely pleased with the results of the exchange, which has improved the companys capital structure, removed most of these complex and dilutive warrants, and reduced the number of fully diluted Aastrom shares by more than six percent. We are now in a much better position to continue to attract high-quality, long-term investors to Aastrom who will no longer have to be concerned about the potential future impact of these warrants, said Tim Mayleben, Aastroms president and chief executive officer.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic cardiovascular diseases. The companys proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patients own bone marrow and delivered directly to damaged tissues. Aastrom has advanced ixmyelocel-T into late-stage clinical development, including a Phase 3 clinical program to study patients with critical limb ischemia and a planned Phase 2b clinical trial in patients with ischemic dilated cardiomyopathy. For more information, please visit Aastroms website at www.aastrom.com. For
more information on the pivotal REVIVE Phase 3 clinical trial, please visit the trial website at www.revivecli.com.
Media contact
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
This document contains forward-looking statements, including, without limitation, the future perception of the capital structure of the company, the companys potential to attract future investors and the quality and nature of such investors, if any. Other forward-looking statements are often, but are not always, made through the use of words or phrases such as anticipates, intends, estimates, plans, expects, we believe, we intend, and similar words or phrases, or future or conditional verbs such as will, would, should, potential, could, may, or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastroms Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward-looking statements reflect managements current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law